$2.77
+0.13 (+4.92%)
Open$2.70
Previous Close$2.64
Day High$2.84
Day Low$2.64
52W High$52.50
52W Low$30.73
Volume—
Avg Volume87.1K
Market Cap12.63M
P/E Ratio40.56
EPS$0.97
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,364.6% upside
Current
$2.77
$2.77
Target
$40.57
$40.57
$36.99
$40.57 avg
$64.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.39M | 5.45M | 4.30M |
| Net Income | -1,299,864 | -1,279,500 | -760,803 |
| Profit Margin | -24.1% | -23.5% | -17.7% |
| EBITDA | -1,608,718 | -1,854,994 | -1,475,925 |
| Free Cash Flow | -1,268,218 | -1,023,573 | -724,682 |
| Rev Growth | -8.0% | -5.0% | +17.9% |
| Debt/Equity | 0.74 | 0.71 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |